medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2011, Number 5

Next >>

Rev Mex Urol 2011; 71 (5)

Renal adenocarcinoma patient followup according to University Integrated Staging System risk groups

Urdiales-Ortiz A, Santana-Ríos Z, Camarena-Reynoso H, Hernández-Castellanos V, Merayo-Chalico C, Saavedra-Briones D, Fulda-Graue S, Pérez-Becerra R, Cantellano-Orozco M, Morales-Montor JG, Pacheco-Gahbler C

Language: Spanish
References: 18
Page: 251-256
PDF size: 312.77 Kb.


ABSTRACT

Objective: To confirm whether there is a difference in recurrence through low risk, intermediate risk, and high risk staging in patients operated on for renal adenocarcinoma.
Methods: A retrospective study was carried out that included patients operated on for renal adenocarcinoma at the Hospital General “Dr. Manuel Gea González” within the time frame of January 1988 to December 2009. Recurrence-free survival was analyzed for all patients according to University Integrated Staging System risk groups.
Results: A total of eighty-nine patients with mean follow- up period of fifty-one months were included in the study. During that time there was recurrence in fifteen patients (16.8%). Recurrence-free rate at five years was 100% for the low risk group, 81% for the intermediate risk group, and 22% for the high risk group. Mean recurrence presentation was twenty-four months in the intermediate risk group and seven and a half months in the high risk group. There was no recurrence in the low risk group.
Conclusions: There is a difference in prognosis for renal adenocarcinoma patients using the University Integrated Staging System. Further studies need to be carried out with larger numbers of patients from different institutions in order to validate this system in the Mexican population.


REFERENCES

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.

  2. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-52.

  3. Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173:1853-62.

  4. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090-5; quiz 1295.

  5. McNichols DW, Segura JW, DeWeerd JH. Renal cell carcinoma: longterm survival and late recurrence. J Urol 1981;126:17-23.

  6. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999;84:405-11.

  7. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163-7.

  8. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 2005;6:7-18

  9. Stephenson AJ, Chetner MP, Rourke K, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004;172:58-62.

  10. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995;154:28-31.

  11. Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for follow-up after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997;157:2067-70.

  12. Montie JE. Follow-up after partial or total nephrectomy for renal cell carcinoma. Urol Clin North Am 1994;21:589-92.

  13. Chin AI, Lam JS, Figlin RA, et al. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol 2006;8:1-7.

  14. Uzzo RG, Novick AC. Surveillance strategies following surgery for renal cell carcinoma. In: Belldegrun AS, Ritchie AW, Figlin RA, et al, Eds. Renal and Adrenal Tumors: Biology and Management. New York: Oxford University Press; 2003.pp.324-330.

  15. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-57.

  16. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22:3316-22.

  17. Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466-72.

  18. Steinbach F, Novick AC, Zincke H, et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol 1995;153:1812-6.




2020     |     www.medigraphic.com